EE Times  Feb 23  Comment 
The Open SystemC Initiative (OSCI) has released a draft of requirements for the configuration portion of the SystemC Configuration, Control & Inspection (CCI) standardization effort. It is open for public review until April 2, 2010.
EE Times  Nov 9  Comment 
The Open SystemC Initiative (OSCI) has moved one step further. It has released a draft of SystemC synthesis subset standard, which is open for public review until Jan. 21, 2010.
Reuters  Sep 29  Comment 
Drug maker Lupin Ltd said on Tuesday it bought U.S. rights for Antara, a cholesterol-lowering drug, for $38.61 million from U.S.-listed Oscient Pharamaceuticals.
FiercePharma  Sep 28  Comment 
Back in January, Oscient Pharmaceuticals filed a patent infringement lawsuit against India's Lupin Pharmaceuticals (LUPN) over the cholesterol drug Antara (fenofibrate). Just days ago, Lupin announced it had purchased the rights to Antara for...
FierceBiotech  Jul 14  Comment 
You can count Oscient Pharmaceuticals among the victims of the economic downturn. The company, a commercial-stage biotech which markets two drugs, filed for bankruptcy protection yesterday. Oscient announced that it had struck a deal to sell its...
Reuters  Jul 13  Comment 
Oscient Pharmaceuticals Corp on Monday filed for Chapter 11 bankruptcy protection and agreed to sell its antibiotic drug Factive to a unit of Cornerstone Therapeutics Inc for $5 million.
StreetInsider.com  Jul 13  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Oscient+Pharmaceuticals+%28OSCI%29+Files+Chapter+11+Bankruptcy%3B+Shares+Deemed+No+Value/4790806.html for the full story.
StreetInsider.com  Jun 11  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Oscient+Pharmaceuticals+%28OSCI%29+Discontinues+Direct+Selling+of+its+Products%3B+Eliminates+150-Person+Sales+Force/4726492.html for the full story.
MarketWatch  Mar 25  Comment 
Oscient Pharmaceuticals said early Wednesday in its fourth quarter 2008 financial report that its auditors have warned it may not be able to continue as a going concern because of lack of cash. The biotechnology company reported that while it had...


Related Articles


Oscient Pharmaceuticals Corporation is a commercial-stage pharmaceutical company that focuses on selling and marketing products to community-based primary care physicians. The company currently has two products in the market Antara and Factive. Antara (fenofibrate) capsule is indicated for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet. Factive (gemifloxacin mesylate) tablet is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity. Besides this, Oscient has a novel, late-stage antibiotic candidate, Ramoplanin, under investigation for the treatment of Clostridium difficile-associated disease (CDAD).

In 2006, Oscient earned $46.2 million in revenue, 82.7% of which came from product sales. Other revenues, consisting primarily of sublicensing revenues related to Factive, accounted for the balance 17.3%. Based on preliminary results, the company expects to post total revenues of approximately $80 million in 2007, representing 73% y-o-y growth. Headquartered in Waltham, Massachusetts, Oscient employs 336 people.


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki